

FORM PTO-1390 (Modified) U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE (REV. 12-2004)		ATTORNEY'S DOCKET NUMBER <b>PU4687US</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>10/522052</b>
INTERNATIONAL APPLICATION NO. <b>PCT/US2003/022716</b>	INTERNATIONAL FILING DATE <b>21 July 2003</b>	PRIORITY DATE CLAIMED <b>23 July 2002</b>
TITLE OF INVENTION <b>PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS</b>		
APPLICANT(S) FOR DO/EO/US <b>M. L. BROWN; M. CHEUNG; S. H. DICKERSON; D.M. GARRIDO; W. Y. MILLS, Y. MIYAZAKI; A. J PEAT; J. P. PECKHAM; T. L. SMALLEY; S. A. THOMSON; J.M. VEAL; J.L. R. WILSON</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a submission under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.</li> <li>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371 (c)(2))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto.</li> <li>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</li> </ol> </li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))             <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409).</li> <li>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> </ol>		
Items 13 to 23 below concern document(s) or information included:		
<ol style="list-style-type: none"> <li>13. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment.</li> <li>16. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>17. <input type="checkbox"/> A substitute specification.</li> <li>18. <input checked="" type="checkbox"/> A power of attorney and/or change of address letter.</li> <li>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</li> <li>20. <input type="checkbox"/> A second copy of the published International Application under 35 U.S.C. 154(d)(4).</li> <li>21. <input type="checkbox"/> A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).</li> <li>22. <input checked="" type="checkbox"/> Express Mail Label No. <b>EV332065482US</b></li> <li>23. <input checked="" type="checkbox"/> Other items or information: copies of: PCT publication cover page (WO2004/009602 A1); PCT Request; PCT/IB/306 PCT Search Report; PCT IPER</li> </ol>		

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.6)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER	
<b>107522052</b>		<b>PCT/US2003/022716</b>		<b>PU4687USw</b>	
24. The following fees are submitted:					
<input checked="" type="checkbox"/> a) Basic national fee ..... <b>\$300.00</b> <input checked="" type="checkbox"/> b) Examination fee ..... <b>\$200.00</b> <input checked="" type="checkbox"/> c) Search fee ..... <b>\$500.00</b>			<b>ATTORNEY'S DOCKET NUMBER</b> <b>Applicant use</b> <b>Office use</b> <b>\$</b> <b>\$300.00</b> <b>\$</b> <b>\$200.00</b> <b>\$</b> <b>\$500.00</b> <b>\$</b> <b>\$1,000.00</b>		
<b>TOTAL OF ABOVE CALCULATIONS = \$1000.00</b>					
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.					
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole)		RATE	
296 - 100 =	196 /50 =	4		x \$250.00	\$ <b>\$1,000.00</b>
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)).					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	x \$50.00	\$	<b>\$0.00</b>
Independent claims	5 - 3 =	2	x \$200.00	\$	<b>\$400.00</b>
MULTIPLE DEPENDENT CLAIMS (if applicable) <input type="checkbox"/> + \$360.00 <b>\$0.00</b>					
<b>TOTAL OF ABOVE CALCULATIONS = \$2,400.00</b>					
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.					
<b>SUBTOTAL = \$2,400.00</b>					
Processing fee of <b>\$130.00</b> for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					
<b>TOTAL NATIONAL FEE = \$2,400.00</b>					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + \$0.00					
<b>TOTAL FEES ENCLOSED = \$2,400.00</b>					
Amount to be refunded: <b>\$</b>					
Amount to be charged: <b>\$</b>					
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <b>07-1392</b> in the amount of <b>\$2,400.00</b> to cover the above fees. A duplicate copy of this sheet is _____. c. <input checked="" type="checkbox"/> The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <b>07-1392</b> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING: Information on this form may become public. Credit card information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status.					
SEND ALL CORRESPONDENCE TO: Customer Number 23347					
 SIGNATURE <b>John L. LEMANOWICZ</b> NAME <b>37,380</b> REGISTRATION NUMBER					

**CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)**

Applicant(s): Matthew Lee BROWN

Docket No  
**107522052**

PU4687USw

DT01 Rec'd PCT/PTC 20 JAN 2005

Serial No.

Filing Date

Examiner

Group Art Unit

To be determined

Invention: PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS

I hereby certify that the following correspondence:

**US application under 35 USC 371 with corresponding papers***(Identify type of correspondence)*

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

January 20, 2005*(Date)*Elaine Martens*(Typed or Printed Name of Person Mailing Correspondence)**(Signature of Person Mailing Correspondence)***Express Mail Label****EV332065482US***("Express Mail" Mailing Label Number)***Documents sent with this 371 Application:**

Post Card=1, Cert of Mail=1

371 Transmittal Sheets=3; IDS+1449=3

Oath/Dec=24; Preliminary Amend=13

Copies of: PCT coversheet/PCT request/

PCT Search Rpt/IPER=27, **PCT/IB/306**